Edixomed has assembled a strong team of directors, managers, scientists, clinicians, contractors and advisors who are confident about the technology's ability to have a positive impact on patients' lives and are determined to ensure its success.
Our products have already shown safety and efficacy in initial clinical studies and the wound dressing has completed its first randomised, controlled clinical trial, which will lead to marketing authorisation.
Edixomed has a board of directors with a strong record of success in pharmaceutical and medical device company start-ups.
The directors have, in the recent past, taken early stage products through all stages of clinical and commercial development, from pre-clinical research programmes, through all phases of clinical development in Europe, U.S and Japan, and set up marketing teams in Europe. They have considerable experience of the regulatory pathway in Europe and the U.S. With a broad range of experience, the team have a great synergy which has enabled them to work together successfully in the past.
Chris Wood. Chairman & Chief Medical Officer
Chris Wood has more than 20 years of experience in the biotechnology sector, having founded and directed 4 successful companies. Chris is Chairman and Chief Medical Officer of Edixomed Limited.
He was co-founder, Chairman and CEO of Bioenvision Inc from 1999, and under his leadership Bioenvision grew from a modest entrepreneurial venture to a leading biotech company (NASDAQ: BIV), with a market capitalisation of $345 million. Bioenvision was acquired by Genzyme Corporation in October 2007.
Chris was co-founder of Medirace Ltd, a start up biotechnology company, which later became Medeva PLC, traded on the London Stock Exchange and the New York Stock Exchange, and was acquired by Celltech Group PLC (now UCB) for £554 million.
Chris Wood is an honorary Professor at Imperial College London, holds an M.D. from the University of Wales School of Medicine and is a Fellow of the Royal College of Surgeons of Edinburgh. Chris Wood's specialty interests are Cancer and Molecular Biology and he has acquired an international reputation for his published work in these areas.
Syd Hanna. Chief Executive Officer
Syd Hanna has more than twenty years of experience in the capital markets and financial industry, having founded, managed and divested portfolio companies in Energy, Industrial and Life Science.
He established Synergy GC, a $1.5bn Fund and Advisory group, previously founded a $13bn Asset Finance business and managed the Capital Markets franchise at Abbey National.
Syd supports a number of companies including early stage biopharmaceutical companies as Director, investor and Executive and is a Partner of Elixir Ventures.
Syd is a Chartered Global Management Accountant and holds a BSc (Hons) Banking & Finance.
Keith Lipman. Non-Executive Director
Keith is an investor in, and advisor to, a portfolio of companies principally in the data and scientific fields.
Keith earned his PhD in Astrophysics from Cambridge University in 1992, studying the early chemical evolution of the Universe, and then turned his focus to applying the same scientific techniques to financial data.
Keith was a founder of a group of companies created to use scientific research to design algorithms to predict the future movements of financial securities. These algorithms were used by bespoke computer systems to trade fully autonomously 24x7 around the world, without human input. In its heyday, this proprietary firm was one of the largest trading firms in the financial markets.
Keith has been a shareholder in Edixomed since 2012, and a Director since 2014.
Justin Barnes. Non-Executive Director
Justin Barnes has over twenty years experience in the healthcare and biopharmaceutical industries, having held a variety of senior board and executive director positions. Justin is a non-executive director of Edixomed.
During the nineties, Justin was part of a pioneering team that developed a small medical device company into a market-leading international business, with a global footprint, culminating in the company's highly successful acquisition by an overseas conglomerate, a process he also led.
Justin was a co-founder and a major shareholder in First Water, a novel biomaterials company focusing on the research, development and manufacture of proprietary finished products for the treatment of chronic skin disorders, medicinal delivery, and consumer health applications. First Water was sold to Scapa PLC in February 2015, after which Justin served as Scapa Healthcare's European MD until his departure in July 2016.
Prior to his business career, Justin was a soldier serving with the Corps of Royal Engineers.
Hugh Griffith. Non-Executive Director
Hugh Griffith has over twenty two years experience in the biopharmaceutical industry, having held Chair, CEO, COO and Executive Director positions. Hugh also serves as CEO and gatekeeper of Alida Capital International, a specialist biopharmaceutical business angel syndicate, which he formed in 2009. He is actively involved in several emerging biopharmaceutical companies, including Nucana BioMed, MedAnnex and OncoBioPharm, as co-founder, director, investor and/or advisor. Hugh also serves on the Board of the Scottish Lifesciences Association and Chairs the Finance Special Interest Group.
As former CEO of Bioenvision, Hugh led the company’s operations from start-up to a global, fully integrated, NASDAQ National Market listed biopharmaceutical company. He was instrumental in increasing Bioenvision’s market capitalization from $22 million to $345 million in 5 years, culminating in the company’s successful acquisition.
Hugh has wide pharmaceutical experience having held numerous positions in Abbott Laboratories and Parke-Davis Warner Lambert. He has an active global network of business angels, researchers, regulators, analysts, and institutional investors.
Chris Wood. Chairman & Chief Medical Officer
Syd Hanna. Chief Executive Officer
Carl Daintree. Chief Operating Officer
Carl Daintree has almost 20 years of experience in the pharmaceutical industry. Recently, Carl was owner/director of a company delivering training internationally on leadership, management and sales skills.
Previously Carl was Associate Director of Operations and Training responsible for the European haematology and transplant division of Genzyme, managing a portfolio of 4 established products and launching a new stem cell mobilisation treatment. Carl is experienced in EU regulatory procedures, market entry, marketing and sales.
Carl has worked with Hugh Griffith and Chris previously at Bioenvision until the acquisition in 2007. Carl was part of the strategic decision making team and also responsible for the training and development of the EU team.
Carl has a BSc with Honours in Applied Biology and extensive pharmaceutical industry experience, having held numerous positions in Janssen Cilag, Pharmacia, Astra and Stiefel.
Dr Hugh Munro. Chief Scientific Officer
Hugh is an accomplished polymer scientist. After an early career researching and lecturing in Physical Chemistry at Durham University, Hugh spent 5 years at Courtaulds PLC where he established and managed a new research group focusing on surface science of polymeric materials. In 1995, Hugh joined First Water (FW) as the founder employee. The company subsequently developed a wide range of wound dressings that are now sold all over the world. The polymer hydrogels which were the foundation of First Water's products are protected by a range of European and US granted patents.
Author/co-author of circa 80 peer reviewed publications. Inventor/co-inventor of 17 USPO and 12 EPO granted patents.
Martine Morris. Business Manager
Martine is a highly experienced events director and project manager. She has organised 1000’s of events across the globe specialising in food, business, healthcare and wellbeing. She has organised a number of ‘live’ events with numbers from 50 – 5,000 delegates and has a vast experience in dealing with external partners. She also coordinated the Medical Futures Innovation Awards, which have been hosted by many A-list celebrities such Jonathan Ross, Joanna Lumley and Rory Bremner and attended by 800 senior guests including members of the Royal Family, Government Ministers and Industry leaders. All of her events have secured hundreds of pieces of positive media coverage including broadcast, broadsheet, regional & trades.
Martine helped set up the Positive Mental Attitude (PMA) Sports Charity, turning a pocket of excellence in Hackney into a national organisation that through sport helps sufferers of mental health problems regain confidence, independence and reintegration into society.
Phil Andrews, Marketing Director
Phil Andrews has twenty years of experience in the Medical Device industry. A Director and major shareholder of two privately-held business that have exited successfully. The second company, First Water, designed, developed and manufactured advanced wound dressings. Phil led the product development, sales and marketing functions for FW. Following the sale of the company to Scapa PLC in February 2015, he served as Scapa Healthcare’s Global Director of Design and Innovation.
Phil is inventor/co-inventor of several finished product patents.
Prior to working in medical devices, Phil worked in a London-based creative advertising agency. BSc (Hons) Management Sciences, University of Warwick.
Professor David H Lloyd
Emeritus Professor of Veterinary Dermatology, Royal Veterinary College, University of London
Professor Lloyd is Emeritus Professor of Veterinary Dermatology at The Royal Veterinary College. He has continuing involvement in postgraduate teaching and is involved in clinical and microbiological research in companion and farm animals.
Professor Lloyd is a former President of the European Society of Veterinary Dermatology, the European College of Veterinary Dermatology and the Veterinary Wound Healing Association, and founding editor of the journal Veterinary Dermatology. He is an officer of the World Association for Veterinary Dermatology.
Professor Lloyd’s research interests are focused on cutaneous infection and immune responses in companion and farm animals with special interest in colonisation, transmission and pathogenesis of infection by staphylococci, including the emergence of methicillin-resistant staphylococci in domestic animals, antimicrobial resistance and yeasts of the genus, Malassezia.
Mr Andrew Goldberg OBE
Clinical Senior Lecturer in Trauma and Orthopaedics, Royal National Orthopaedic Hospital
Andrew Goldberg OBE is a British orthopaedic surgeon specialising in complex ankle disorders. He is a consultant orthopaedic surgeon at the Royal National Orthopaedic Hospital in London and Stanmore and also an academic at University College London.
Mr. Goldberg runs a research programme exploring regenerative medicine treatments, including stem cells and cartilage transplantation, the effects of stem cell therapy on Achilles tendinopathy, and comparing outcomes of ankle replacements against ankle fusion. He was responsible for the creation of the National Joint Registry for Ankle Replacements. He sits on the Outcomes Committee of the British Orthopaedic Foot and Ankle Society and is leading on several national patient reported outcome measures’ projects including being the musculoskeletal lead of the Farr Institute of Health Informatics.
He chairs the Medical Futures Innovation Awards, and speaks nationally and internationally on healthcare entrepreneurship & innovation, including the Royal Society in London. He has authored several text books and is editor for the Clinical Talk Series, distributed by World Scientific.
He was awarded an OBE in the 2011 New Year Honours for services to medicine.
Professor Graham Cooke
NIHR Professor of Infectious Diseases, Imperial College London
Graham Cooke is NIHR Professor of Infectious Diseases based at the Wright-Fleming Institute, Imperial College London. He works as an NHS consultant at St Mary’s Hospital, Paddington and has active research programmes in both the UK and Vietnam.
His research interests span precision medicine and diagnostics in infection, focussed on blood borne viruses, sepsis and AMR. He is infection lead for the NIHR Medtech and In-vitro Diagnostics Centre, co-chairs the WHO Expert Committee on Essential Medicines and chairs the EML Working Group on anti-microbial resistance.
Professor Art Tucker
Professor of Therapeutic Innovation & Adoption (QMUL), Barts NHS Health Trust
Prof Tucker has served the NHS for over 20 years as a clinical researcher alongside clinical responsibilities in a unique centre for Microvascular medicine. He is responsible for the invention and development of a wide range of award-winning medical devices and novel pharmaceutical agents including Edixomed’s NO generating system and the Geko™ medical device (Firstkind Ltd) for deep vein thrombosis prevention, incontinence and circulatory support.
As Institutional Lead Scientist at Barts Health NHS Trust he acts as technology champion within the NHS and higher education sectors. Committee memberships include the NIHR, NICE and Wellcome Trust.
Alida Capital International Ltd (ACI) is a successful syndicate of business angels who provide capital and practical assistance for emerging biopharmaceutical companies.
Since it was established in 2009, ACI has injected over £15 million investment into Scottish life science companies.
ACI’s smart investment in Scotland generates opportunities for talented entrepreneurs to succeed in the biotechnology and pharmaceutical industry. Our aim is to accelerate emerging companies to significant value inflection points and, in so doing, secure outstanding financial returns for our members.
The Small Business Research Initiative (SBRI) is a well established process to connect public sector challenges with innovative ideas from industry, supporting companies to generate economic growth and enabling improvement in achieving government objectives.
It generates new business opportunities for companies, provides small and medium-sized enterprises (SMEs) a route to market for their ideas and bridges the seed funding gap experienced by many early stage companies. It supports economic growth and enables the development of innovative products and services through the public procurement of research and development (R&D).
Scottish Enterprise identify and exploit opportunities for Scotland's economic growth by supporting Scottish companies to compete, helping to build globally competitive sectors, attracting new investment and creating a world-class business environment.
It works with partners to stimulate economic growth, exploit low carbon opportunities, improve Scotland's business infrastructure and support business.
The Scottish Investment Bank (SIB) is a division of Scottish Enterprise that supports the development of Scotland’s private sector SME funding market to ensure both early stage and established businesses with growth and export potential have adequate access to growth capital.
SIB operates a suite of investment funds. The three equity funds adopt a highly innovative co-investment and shared risk intervention model to encourage more private investors to invest in early stage Scottish companies with high growth potential. SIB is also the lead investor in the privately managed Scottish Loan Fund which operates on a fully commercial basis and is aimed at established companies.
A grant from the MRC funded the completion of the Phase I VAP study.
Medical distributors play a critical role in today’s healthcare environment and we actively seek to explore partnerships to help strengthen the competitiveness of our distribution.
Edixomed is developing new technologies for commercial distribution in the advanced wound care and infection control markets.
Contact us today to find out more about becoming a distributor for Edixomed or if you wish to speak with a member of our business development team.